

March 1, 2023

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Travele Therapeutics, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The required information for the new product being launched is detailed below:

NDC	Product Name	Date Of Release Into Commercial Market
68974-0200-30	Filspari (sparsentan) Oral tablets, 200mg, 30 tablets	2/28/2023
68974-0400-30	Filspari (sparsentan) Oral tablets, 400mg, 30 tablets	3/1/2023

Sincerely,

Sayan Das Mitra

Senior Director, Market Access, Pricing and Contracts

+1-650-255-7887

Sayan.mitra@travele.com